LFA
TBPH icon

Legacy Financial Advisors’s Theravance Biopharma TBPH Stock Holding History

Legacy Financial Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-94
Closed -$2K – 807
2019
Q1 		$2K Hold
94
– – ﹤0.01% 918
2018
Q4 		$2K Hold
94
– – ﹤0.01% 853
2018
Q3 		$3K Hold
94
– – ﹤0.01% 774
2018
Q2 		$2K Hold
94
– – ﹤0.01% 838
2018
Q1 		$2K Hold
94
– – ﹤0.01% 767
2017
Q4 		$2K Buy
+94
New +$2.78K ﹤0.01% 756

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Legacy Financial Advisors's TBPH Position: Q2 2019 in Review

Legacy Financial Advisors sold out of Theravance Biopharma (TBPH) in Q2 2019, closing a stake of 94 shares — an estimated $2K sold.

Legacy Financial Advisors first reported a position in TBPH in Q4 2017 and held it in 6 quarters. The position peaked at $3K in Q3 2018. 98 funds tracked by Wall St. Rank hold TBPH as of Q2 2019.

  • Legacy Financial Advisors reported no remaining Theravance Biopharma position as of Q2 2019 after selling out during the quarter.
  • Legacy Financial Advisors sold 94 Theravance Biopharma shares in Q2 2019, an estimated $2K.
  • Legacy Financial Advisors first reported a position in Theravance Biopharma in Q4 2017 and held it in 6 quarters.
  • Legacy Financial Advisors's Theravance Biopharma position peaked at $3K in Q3 2018.
  • 98 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2019.

Based on Legacy Financial Advisors's 13F filing for Q2 2019, filed 7 Aug 2019.